The third-party peptide testing landscape

A third-party Certificate of Analysis is not just a COA with someone else's logo on it. It is a structurally different document — produced by a laboratory that did not synthesise the material, has no commercial stake in the result, and chose its own analytical methods. For peptide buyers who care about what is actually in the vial, third-party testing is the only practical mechanism short of doing the analytical work yourself.

This article maps the third-party peptide testing landscape: what makes a laboratory genuinely third-party, what to look for in their methods, the recognised names that handle community submissions, and how to read a third-party COA differently from a vendor in-house one.

Why third-party testing exists at all

A manufacturer's in-house Certificate of Analysis is, structurally, a statement that the manufacturer made about its own product. The numerical values may be entirely accurate; the document itself is, by definition, not independent. There is no external check on integration choices, method selection, or whether the certificate corresponds to the vial in front of the buyer at all.

For pharmaceutical-grade peptides released to clinical use, this conflict is managed by regulatory inspections, GMP audits, and batch-release procedures. For research peptides sold into a less regulated market, none of those mechanisms apply. The third-party laboratory exists to provide the independent check that the regulatory framework does not.

Two structural realities make independent testing valuable:

Method neutrality. A laboratory testing on commission has no incentive to choose analytical parameters that flatter the result. An in-house lab might integrate HPLC peaks generously to boost reported purity; a third-party lab returns the chromatogram with the integration software's default values and lets the buyer judge.
Sample-of-record traceability. The buyer submits a portion of the actual vial they hold. The result attaches to that physical sample, not to a generic specification. If the labelled product differs from what the buyer received — wrong peptide, mixed batch, mislabelled potency — independent testing surfaces the discrepancy.

What "third-party" actually means

Not every laboratory that issues COAs on demand is third-party in the meaningful sense. The criteria that matter:

No commercial relationship with the product or its vendor. A laboratory owned by, paid retainer fees by, or otherwise financially aligned with a particular vendor cannot issue independent results about that vendor's products.
Sample chain-of-custody documented. The COA should reference where the sample came from (submitter, sample ID), when it arrived, and how it was handled. Anonymous "we tested some BPC-157" reports are not chain-of-custody documented.
Methods chosen by the laboratory. A genuinely independent lab selects methods appropriate for the analyte from its own validated portfolio. If the vendor dictates the method, the result is closer to a contract test than an independent assessment.
Results returned regardless of outcome. Independent labs report what they observed, including failures of specification. A laboratory that only publishes "pass" results is not testing — it is curating.

Where possible, look for ISO/IEC 17025:2017 accreditation. ISO 17025 is the international standard for the competence of testing and calibration laboratories; accreditation requires an external accreditation body to assess the lab's methods, measurement uncertainty, traceability, and quality management. It is voluntary, expensive, and a strong positive signal — particularly for laboratories that submit themselves to scope-specific accreditation for the methods most relevant to peptide analysis.

What a credible third-party laboratory does

A well-equipped peptide testing laboratory operates roughly the following workflow:

Receive sample. Sealed vial with intact stopper, labelled with submitter-provided ID, accompanied by a submission form that states the analyte, expected molecular weight, sequence (if known), and tests requested.
Pre-analysis assessment. Photograph of the vial, mass-of-contents check, appearance description.
Sample preparation. A portion is weighed (typically 0.5–2 mg) and reconstituted in a defined volume of solvent appropriate for the analytical method.
HPLC purity analysis. Reversed-phase HPLC on a C18 column, water/acetonitrile gradient with 0.1% trifluoroacetic acid or formic acid as ion-pairing agent, UV detection at 215 nm (and often 280 nm), per the principles of USP General Chapter <621> on chromatography.
Mass spectrometry identity confirmation. LC-MS or MALDI-TOF to confirm the observed mass matches the theoretical mass within tolerance.
Optional additional analyses. Counterion content (capillary electrophoresis or ion chromatography), water content (Karl Fischer), endotoxin (LAL), residual solvents (GC-MS).
Report. A Certificate of Analysis that includes the chromatogram, mass spectrum, method details, observed vs specification values, and analyst signature.

The presence or absence of each of these steps on a returned COA tells you what the laboratory actually did versus what they claimed.

Recognised names in peptide community testing

The peptide research community uses a small set of laboratories repeatedly. Inclusion in this list is descriptive — not an endorsement — and buyers should evaluate each lab on its current accreditation, method portfolio, and turnaround based on their own diligence.

Janoshik Analytical (Czech Republic) is one of the most-cited names in research-peptide testing. The lab offers HPLC purity, mass spectrometry identity, and limited additional analyses on submitted vials, with COAs typically including the chromatogram and mass-spec trace. Pricing is per-sample and turnaround is typically a small number of working days.
Echelon Biosciences (United States) is primarily a reagent supplier with an analytical services arm. Their analytical capabilities include HPLC and mass spectrometry across a wider range of bioactive small molecules; peptide testing is one part of a broader portfolio.
Contract pharmaceutical analysis laboratories — companies like Eurofins, SGS, and several smaller ISO 17025-accredited contract labs in the US, EU, and Australia. These typically operate at higher cost points than community-oriented labs but bring stricter accreditation and method validation packages, useful if the result needs to support regulatory or publication contexts.
University core facilities. Some buyers — particularly academic researchers — use their institution's mass spectrometry or proteomics core. The methods are first-class, but turnaround and report formatting depend entirely on local arrangements.

What no list of laboratories solves is the question of which methods the lab will use for which compound. A laboratory that runs a generic reversed-phase HPLC method on every submitted vial is faster but less informative than one that adapts its method to the analyte's chromatographic behaviour. Ask the laboratory, in advance, what method they will use.

How testing actually works

The process from submission to result, in brief:

Take a representative sample. For lyophilised peptides, this typically means submitting the unopened vial or a sealed aliquot. Avoid sampling techniques that contaminate the remainder of the stock.
Package for shipping. Sealed in tamper-evident packaging, with the labelled peptide name, lot number, and submitter contact information. Cold packs are not strictly required for most lyophilised peptides but are common practice.
Submit with a method request. The submission form should specify which tests are required (purity, identity, counterion, water content, endotoxin) and any relevant context — expected molecular weight, sequence, previous testing results, observed appearance.
Receive the report. Typically a PDF Certificate of Analysis with the chromatogram and mass spectrum embedded. Some labs provide raw data files on request.

The cost of a basic purity + identity test, at community-oriented labs, is approximately 100–250 USD per sample. Full panels with counterion, water, residual solvents, and endotoxin run substantially higher.

Reading a third-party COA differently

A third-party COA should be read with different attention than an in-house one:

The chromatogram is the document. A third-party COA without an attached chromatogram is structurally incomplete. The numerical purity is derived from the chromatogram; without it, the number is unverifiable. Reputable laboratories include the trace as a separate page or embedded image.
The method details belong in the report. Column dimensions and chemistry, mobile phase composition, flow rate, gradient profile, injection volume, detection wavelength, and any internal references should be readable. A method described as "HPLC" without further specification is not a method.
Numerical values, not pass/fail. "Purity by HPLC: 98.7%, area percent at 215 nm" is a measurement. "Purity: PASS" is a marketing assertion that happens to be on a third-party letterhead.
Date of analysis, not date of certificate. When the sample was actually run matters; the certificate is often issued a few days later. Both dates should be visible.
Discrepancies with the vendor COA. If a third-party result differs materially from the vendor's in-house result — a percentage of purity, a mass identification, a counterion content — the discrepancy is the most informative datum on either certificate. It deserves an explanation.

When third-party testing disagrees with the vendor

Disagreements happen. They can arise from:

Sample heterogeneity. Particularly for hygroscopic peptides, two samples drawn from the same lot can have different water contents and therefore different effective potencies. A 5% mass discrepancy is not uncommon between vials of nominally the same product.
Method differences. A laboratory using a different HPLC column or gradient may resolve impurity peaks that the vendor's method coelutes with the main peak. The result is a slightly lower reported purity. Whichever method is more selective is the more honest measurement.
Sample handling. Improper sampling — exposure to air, repeated freeze-thaw — degrades peptides. A third-party result that shows degradation products absent from the vendor COA may indicate handling rather than synthesis quality.
Mislabelling or substitution. The most consequential disagreement. If a third-party laboratory cannot confirm the expected molecular mass, the product is not what the label says it is.

A vendor that responds substantively to a third-party result that disagrees with their COA — explaining the discrepancy, offering to re-test, or replacing the batch — is one worth continuing to work with. A vendor that dismisses or attacks the third-party laboratory is one worth re-evaluating.